View:
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation
Statement
Under Section
14(d)(4) of the Securities Exchange Act of 1934
LISATA THERAPEUTICS, INC.
(Name of Subject
Company)
LISATA THERAPEUTICS, INC.
(Name of Person
Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class
of Securities)
128058302
(CUSIP Number of
Class of Securities)
David J. Mazzo,
Ph.D.
Chief Executive
Officer
Lisata
Therapeutics, Inc.
110 Allen Road,
Second Floor
Basking Ridge, NJ
07920
(908) 841-0100
(Name, Address
and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the
Person Filing Statement)
With copies to:
Jeffrey P.
Schultz, Esq.
Ivan Presant,
Esq.
Mintz Levin Cohn
Ferris Glovsky &
Popeo, P.C.
919 Third Avenue
New York, NY
10022
(212) 935-3000
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Item 8.01 of the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. on April 15, 2026 (including all exhibits attached thereto and incorporated therein by reference) is
incorporated herein by reference.